Debate Rages Over Direct-to-Consumer Drug Ads

Proponents say ads empower patients, while critics argue they promote overuse of expensive new medications.

Published on Feb. 17, 2026

Got story updates? Submit your updates here. ›

The debate over direct-to-consumer prescription drug advertising has reignited, with the Trump administration and some lawmakers pushing to limit or ban such ads. Supporters argue the ads provide valuable information and education to patients, while opponents say they encourage overuse of expensive new drugs that don't offer significant therapeutic advantages over older, cheaper options. The issue is particularly relevant for older adults, who take more medications and are frequent targets of drug marketing.

Why it matters

Direct-to-consumer drug ads have become ubiquitous, with pharmaceutical companies spending billions annually on TV, radio, print, and digital campaigns. Critics contend these ads drive up healthcare costs by prompting patients to request brand-name drugs, even when generic or older alternatives may be just as effective. Supporters counter that the ads empower patients and lead to increased use of both advertised and non-advertised medications, including generics.

The details

In 2022, Novo Nordisk, the maker of the diabetes drug Ozempic, spent an estimated $180 million on direct-to-consumer advertising, a figure that grew to $201 million by 2023. Overall, direct-to-consumer drug ad spending topped $9 billion last year. Research has shown these ads influence prescription rates, as patients request specific drugs and doctors often comply. However, a 2023 study found that nearly three-quarters of the most heavily advertised medications provided little additional therapeutic value over older, cheaper options.

  • In 1997, the FDA loosened restrictions on prescription drug ads on television.
  • In 2006, the introduction of Medicare Part D led to a significant increase in pharmaceutical advertising.
  • In 2023, the Trump administration called for a return to the pre-1997 policy severely restricting direct-to-consumer drug advertising.
  • In February 2026, the FDA notified Novo Nordisk that a TV ad for a new oral version of Wegovy was false and misleading.

The players

Tamar Abrams

A 69-year-old woman who started taking the diabetes drug Ozempic after seeing its joyful TV ads, leading to a 90-pound weight loss and improved health.

Dr. Steven Woloshin

A researcher at the Dartmouth Institute who studies health communication and decision-making, and advocates for more effective educational campaigns to help consumers become more skeptical of drug ads.

Abby Alpert

A health economist at the Wharton School of the University of Pennsylvania who argues that direct-to-consumer ads benefit consumers by providing information and leading to increased use of both advertised and non-advertised medications.

Dr. Aaron Kesselheim

The senior author of a 2023 study that found nearly three-quarters of the most heavily advertised medications provided little additional therapeutic value over older, cheaper options.

Robert F. Kennedy Jr.

The Health and Human Services Secretary who has charged that "pharmaceutical ads hooked this country on prescription drugs" and called for a return to the pre-1997 policy restricting such ads.

Got photos? Submit your photos here. ›

What they’re saying

“Often, really good drugs sell themselves. Drugs without added therapeutic value need to be pushed, and that's what direct-to-consumer advertising does.”

— Dr. Aaron Kesselheim, Director of the Program on Regulation, Therapeutics and Law at Harvard University

“It provides information and education to patients, makes them aware of available treatments and leads them to seek care. That is especially important for underdiagnosed conditions, like depression.”

— Abby Alpert, Health economist at the Wharton School of the University of Pennsylvania

“There's a lot of chatter. I don't know that we'll see anything concrete.”

— Dr. Steven Woloshin, Researcher at the Dartmouth Institute

What’s next

The FDA has notified Novo Nordisk that a TV ad for a new oral version of Wegovy was false and misleading, and the company is in the process of responding to address the agency's concerns.

The takeaway

The debate over direct-to-consumer drug advertising highlights the tension between empowering patients with information and driving up healthcare costs through the promotion of expensive new medications that may not offer significant advantages over existing options. As policymakers and regulators weigh potential restrictions, consumers must remain vigilant and skeptical when evaluating the claims made in these ubiquitous ads.